Canaccord analyst William Maughan lowered the firm’s price target on Y-mAbs Therapeutics to $20 from $23 and keeps a Buy rating on the shares. The analyst noted they announced a restructuring, with cost/headcount reductions, effectively increasing focus on Danyelza and the SADA platform. He noted the Danyelza 2023 revenue guidance of $60-65M dumps some cold water on expectations for a more drastic inflection.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on YMAB:
- Y-mAbs Therapeutics downgraded to Market Perform from Outperform at Cowen
- Y-mAbs Therapeutics announces strategic objectives for FY23
- Y-mAbs Therapeutics announces restructuring plan, to reduce workforce by 35%
- Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA
- Y-mAbs Therapeutics enters distribution agreement with WEP Clinical
